Companies /Healthcare

Mckesson Corporation

NYSE: MCK Medical Distribution
$960.56
▼ $6.46 (−0.67%) today
Markets closed · 10:54pm ET

24/7 Wall St. View

Price Prediction $1,119.88 +16.3% Our analysts’ 12-month view: target, optimistic case, and floor. MCK price prediction → Earnings Beat +4.1% EPS vs. the estimate, revenue, and how the market reacted. MCK earnings history →

MCK at a Glance

Valuation
Market cap
$112.7B
P/E ratio
25.9
Dividend yield
0.33%
Profitability
Revenue (TTM)
$411.0B
Profit margin
1.1%
EPS (TTM)
$37.31
Price
52-week range
$722 – $1,030
24/7 target
$1,119.88
Street target
$1,009.64
Earnings
Next report
Nov 4, 2026
Q1 2027 EPS
$9.93
vs. $9.54 est.
+4.1%

Headquartered in Irving, TX Fiscal year ends March NYSE: MCK mckesson.com

About McKesson

McKesson Corporation is a diversified healthcare services company that partners with biopharma companies, care providers, pharmacies, manufacturers, and governments to deliver pharmaceutical distribution, oncology and multispecialty solutions, prescription technology services, and medical-surgical supply distribution. The company operates four reportable segments: North American Pharmaceutical (its largest segment by revenue, distributing branded, generic, specialty, and biosimilar pharmaceuticals), Oncology & Multispecialty (providing provider solutions, specialty drug distribution, and practice management for oncology and other specialty practices), Prescription Technology Solutions (offering third-party logistics, access and adherence solutions, and technology services to biopharma companies), and Medical-Surgical Solutions (distributing medical-surgical supplies and specialty pharmaceuticals to alternate sites of care, which is being separated into a standalone public company named Wellverse). McKesson serves as a critical intermediary in the U.S. healthcare supply chain, handling prescription transaction volumes and specialty product distribution at scale. Updated

Revenue by Segment · Q1 2027
  1. North American Pharmaceutical82%
  2. Oncology & Multispecialty13%
  3. Medical-Surgical Solutions3%
  4. Prescription Technology Solutions1%

Latest Activity

MCKMcKesson
New 52-week high$998.64+0.5% vs prior high · 2026-03-03

McKesson just set a fresh 52-week high at $998.64, knocking on $1,000 for the first time. The distributor has clawed back a summer drawdown that took it under $740.

Read more
Biggest movers · On the open
Gainers
  • ACNAccenture$224.22+22.3%
  • SNPSSynopsys$472.79+8.7%
  • APPSDigital Turbine$11.87+6.9%
  • MCKMcKesson$904.75+6.0%
  • IBMIBM$232.95+5.9%
Losers
  • CTVACorteva$13.96-82.0%
  • NWGNatWest Group$17.54-3.4%
  • MTArcelorMittal$64.71-3.0%
  • HSBCHSBC$96.31-3.0%
  • APDAir Products & Chemicals$270.24-2.9%

Accenture opened 22% higher, a move you almost never see from a mega-cap IT services name, while Corteva dropped 82% to $13.96 at the other end of the board. Synopsys, McKesson and IBM round out a gainers list that is all up at least 5.9%.

Read more

MCK Coverage

Load More

Frequently Asked Questions

What does McKesson do?

McKesson Corporation is a diversified healthcare services company that partners with biopharma companies, care providers, pharmacies, manufacturers, and governments to deliver pharmaceutical distribution, oncology and multispecialty solutions, prescription technology services, and medical-surgical supply distribution.

What is the MCK stock price target?

24/7 Wall St.'s 12-month price target for MCK is $1,119.88, rated Buy. The Wall Street consensus target is $1,009.64. MCK price prediction →